featured
2022 Top Story in Oncology: Results From the Phase II KEYNOTE-158 Study
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394-424.
- Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33.
- Alexa M, Hasenburg A, Battista M. The TCGA Molecular Classification of Endometrial Cancer and Its Possible Impact on Adjuvant Treatment Decisions. Cancers (Basel). 2021;23;13(6):1478.
- Talhouk A, McConechy MK, Leung S, et al. A Clinically Applicable Molecular-Based Classification for Endometrial Cancers. Br J Cancer. 2015;113(2):299-310.
- McAlpine J, Leon-Castillo A, Bosse T. The Rise of a Novel Classification System for Endometrial Carcinoma; Integration of Molecular Subclasses. J Pathol. 2018;244(5):538-549.
- O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. J Clin Oncol. 2022;40(7):752-761.
- Makker V, Colombo N, Herráez AC, et al. Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. N Engl J Med. 2022;386(5):437-448.
Disclosure statements are available on the authors' profiles: